Scancell Holdings (LSE:SCLP) Debt-to-Asset

: 0.89 (As of Oct. 2023)

View and export this data going back to 2010. Start your Free Trial

Scancell Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was £0.31 Mil. Scancell Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was £19.51 Mil. Scancell Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Oct. 2023 was £22.25 Mil. Scancell Holdings's debt to asset for the quarter that ended in Oct. 2023 was 0.89.

Scancell Holdings Debt-to-Asset Historical Data

The historical data trend for Scancell Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Debt-to-Asset

0.02

0.31

0.49

0.65

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
Debt-to-Asset																0.18	0.49	0.25	0.65	0.89

Competitive Comparison

For the Biotechnology subindustry, Scancell Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scancell Holdings Debt-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Debt-to-Asset falls into.

Scancell Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Scancell Holdings's Debt-to-Asset for the fiscal year that ended in Apr. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.306	+	19.227)	/	30.27
	=	0.65

Scancell Holdings's Debt-to-Asset for the quarter that ended in Oct. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.306	+	19.509)	/	22.252
	=	0.89

Scancell Holdings (LSE:SCLP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Scancell Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (LSE:SCLP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCP:Germany

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines